Similar articles

• Long-term survival after combined modality treatment in metastatic bladder cancer patients presenting with supra-regional tumor positive lymph nodes only.

  de Vries RR, Nieuwenhuijzen JA, Meinhardt W, Bais EM, Horenblas S. de Vries RR, et al. Eur J Surg Oncol. 2009 Apr;35(4):352-5. doi: 10.1016/j.ejso.2008.07.001. Epub 2008 Aug 22. Eur J Surg Oncol. 2009. PMID: 18722076
• Adjuvant polychemotherapy of nonorgan-confined bladder cancer after radical cystectomy revisited: long-term results of a controlled prospective study and further clinical experience.

  Stöckle M, Meyenburg W, Wellek S, Voges GE, Rossmann M, Gertenbach U, Thüroff JW, Huber C, Hohenfellner R. Stöckle M, et al. J Urol. 1995 Jan;153(1):47-52. doi: 10.1097/00005392-199501000-00019. J Urol. 1995. PMID: 7966789 Clinical Trial.
• Clinical outcome in patients with locally advanced bladder carcinoma treated with conservative multimodality therapy.

  George L, Bladou F, Bardou VJ, Gravis G, Tallet A, Alzieu C, Serment G, Salem N. George L, et al. Urology. 2004 Sep;64(3):488-93. doi: 10.1016/j.urology.2004.04.088. Urology. 2004. PMID: 15351577 Review.
• Extended experience of neo-adjuvant M-VAC chemotherapy for T1-4 N0 M0 transitional cell carcinoma of the urinary bladder.

  Keating JP, Zincke H, Hahn RG, Morgan WR. Keating JP, et al. Prog Clin Biol Res. 1990;353:119-27. Prog Clin Biol Res. 1990. PMID: 2217409 No abstract available.
• [Neoadjuvant chemotherapy with MVC (methotrexate, vinblastine, cisplatin)in the treatment of infiltrating transitional carcinoma of the bladder].

  Campo B, Torelli T, Leidi GL, Corrada P, Bacchioni AM, Ordesi G, Zanitzer L. Campo B, et al. Arch Ital Urol Nefrol Androl. 1990 Jun;62(2):237-42. Arch Ital Urol Nefrol Androl. 1990. PMID: 2142807 Review. Italian.